Effects of drospirenone/estrogen combinations on bone metabolism

@article{Christiansen2005EffectsOD,
  title={Effects of drospirenone/estrogen combinations on bone metabolism},
  author={C. Christiansen},
  journal={Climacteric},
  year={2005},
  volume={8},
  pages={35 - 41}
}
Bone mass is maintained when low-dose ethinylestradiol is used in combination with the new progestogen drospirenone as an oral contraceptive, making a regimen of drospirenone combined with 17β-estradiol an attractive option for hormone replacement therapy (HRT) in postmenopausal women. Drospirenone is a novel progestogen, more closely related to endogenous progesterone in its pharmacological properties than other progestogens available; in combination with estrogen, drospirenone can closely… Expand
THE EFFECTS OF LOW DOSE HORMONE THERAPY ON SERUM LIPID PROFILE, GLISEMIC CONTROL, THYROID HORMONES AND ANDROGEN LEVELS IN POSTMENOPAUSAL WOMEN
TLDR
NETA have beneficial effects on both lipid and carbohydrate metabolism in postmenopausal women and under the light of these data it is wise to suggest NETA containing low dose hormone therapy preparations in post menopausal women with diabetes risk for controlling vasomotor complaints. Expand
Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms
  • O. Ylikorkala
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2005
TLDR
A novel progestin is introduced, drospirenone, to be used in combination with ethinylestradiol for oral contraception or with estradiol with potentially harmful side-effects which are potentially harmful and reduce the tolerability of the contraceptive pill or HT. Expand
Clinical experiences with drospirenone: from reproductive to postmenopausal years.
TLDR
A retrospective study of published information concerning DRSP retrieved from both a PubMed and a personal search finds these OCs appear to improve many of the symptoms associated with premenstrual complaints and dysphoric disorders, including negative mood, water retention and increased appetite. Expand
Long-term effects of progestins on bone quality and fractures
  • J. Thijssen
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2007
TLDR
In postmenopausal women, no evidence has been found for a bone-protective or an estrogen-antagonistic effect of progestin, and a wide range of estrogens have been used that have shown positive effects on bone, which are not antagonized by progestins. Expand
Effect of a mixture of calcium, vitamin D, inulin and soy isoflavones on bone metabolism in post-menopausal women: a retrospective analysis
TLDR
These results suggest that the considered mixture improved intestinal calcium absorption and bone metabolism in post-menopausal women. Expand
Estrogen counteracts ozone-induced oxidative stress and nigral neuronal death
TLDR
Results indicate that ozone exposure may be a useful Parkinson's disease model and neuroprotection afforded by 17&bgr;-estradiol is dependent on the high levels achieved after its prolonged administration. Expand
Telbivudine (Tyzeka) for Chronic Hepatitis B
  • Medicine
  • The Medical letter on drugs and therapeutics
  • 2007
TLDR
Chronic HBV infection is currently treated with weekly injections of pegylated interferon alfa (Pegasys), or oncedaily oral treatment with a nucleoside analog such as lamivudine or entecavir or the nucleotide analog adefovir. Expand

References

SHOWING 1-10 OF 21 REFERENCES
Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis
TLDR
Although endometrial thickness increased slightly, the safety of the endometrium was assured, as no cases of hyperplasia or cancer occurred, and the combination of 17β-estradiol and drospirenone has a positive effect on BMD and a potentially beneficial effect on lipids. Expand
Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.
TLDR
Based on the biochemical and pharmacodynamic data, drospirenone appears to be a viable alternative to the currently available progestogens. Expand
Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties.
  • A. Rübig
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2003
TLDR
Phase III studies with E2/DRSP show that DRSP does not antagonize the well-documented reductions of blood pressure associated with E1; rather, small DRSP dose-related reductions in systolic and diastolic blood pressures were observed, which should be beneficial for recipients, especially those who are mildly hypertensive. Expand
Pharmacology of estradiol valerate/dienogest.
  • A. Teichmann
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2003
TLDR
E2V/DNG is well suited as an effective hormone replacement therapy, with the potential for good bleeding patterns and low androgenicity, owing to its formulation with a progestogenic component that is highly endometriotropic, has low antiestrogenicity and exhibits considerable antiandrogenicity. Expand
Effect of Continuous Combined Estrogen and Desogestrel Hormone Replacement Therapy on Serum Lipids and Lipoproteins
TLDR
The results indicate that when desogestrel 0.15 mg/day is combined with micronized 17β-E2 1mg/day in a continuous manner, the effects of the progestogen on HDL predominate and cause a reduction in HDL and the HDL2 subtraction. Expand
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
TLDR
Overall health risks exceeded benefits from use of combined estrogen plus progestin for an average 5.2-year follow-up among healthy postmenopausal US women, and the results indicate that this regimen should not be initiated or continued for primary prevention of CHD. Expand
Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
TLDR
All the treatment regimens produced changes in levels of serum lipids, lipoproteins, and apolipoproteins that may be considered favorable in terms of cardiovascular disease. Expand
Early postmenopausal hormone therapy may prevent cognitive impairment later in life
TLDR
The results of the present study suggest that previous short-term HT administered in the early phase of the menopause may provide a long-term protection against cognitive impairment. Expand
LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN EVIDENCE FOR AN INCREASED BONE MASS AFTER DELAYED ONSET OF ŒSTROGEN TREATMENT
TLDR
Treatment of 63 oophorectomised women with oestrogen for five years prevented the reduction in bone mineral content observed in 57 women treated with a placebo preparation, and the expected biochemical effects of oestrogens therapy persisted for at least three years, and were compatible with a prolonged increase in parathyroid activity but a reduction inBone turnover. Expand
Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
TLDR
Limited HRT administered in the early postmenopausal years offers long-lasting benefits for the prevention of post menopausal bone loss and osteoporotic fracture. Expand
...
1
2
3
...